ACTG 326: ALVAC HIV VACCINE IN CHILDREN BORN TO HIV INFECTED MOTHERS

ACTG 326：为感染 HIV 的母亲所生的孩子提供 ALVAC HIV 疫苗

• 批准号: 6264292
• 负责人: ELIZABETH G MCFARLAND
• 金额: $ 1.99万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264292
• 关键词: AIDS therapy; AIDS vaccines; HIV infections; Poxviridae; cellular immunity; clinical research; clinical trial phase I; cytotoxic T lymphocyte; drug screening /evaluation; helper T lymphocyte; human subject; human therapy evaluation; humoral immunity; immunoglobulin A; immunoglobulin G; infant human (0-1 year); lymphocyte proliferation; mucosal immunity; recombinant virus; vertical transmission; virus antigen; virus load

There are two specific aims. The two primary aims are 1) to determine the safety of live recombinant Canarypox ALVAC HIV vaccine in infants who are of indeterminate status born to HIV-infected women; 2) to evaluate humoral and cell-mediated responses including cytotoxic T cell and lympho- proliferative responses to HIV-specific antigens and non-HIV antigens in immunized infants. The two secondary aims are 1) to review changes in viral load over time in infants proven to be infected and absolute CD4 counts in all immunized infants; 2) to evaluate whether changes in HIV-specific IgG and IgA in the mucosal secretions can be detected.

有两个具体目标。 两个主要目标是 1) 确定重组金丝雀痘 ALVAC HIV 活疫苗对 HIV 感染妇女所生婴儿的安全性； 2) 评估免疫婴儿中体液和细胞介导的反应，包括细胞毒性 T 细胞和对 HIV 特异性抗原和非 HIV 抗原的淋巴细胞增殖反应。 两个次要目标是 1) 审查已证明感染的婴儿病毒载量随时间的变化以及所有免疫婴儿的绝对 CD4 计数； 2)评价是否能检测到粘膜分泌物中HIV特异性IgG和IgA的变化。